
{
    "credit": [
        {
            "email": "leon.stefanovski@charite.de",
            "name": "Leon Stefanovski",
            "typeEntity": "Person",
            "typeRoles": [
            ]
        }
    ],
    "documentation": [
        {
            "type": "User manual",
            "url": "http://adni.loni.usc.edu/wp-content/themes/freshnews-dev-v2/documents/clinical/ADNI3_Protocol.pdf"
        }
    ],
    "function": [
        {
            "operation": [
                {
                    "term": "Essential dynamics",
                    "uri": "http://edamontology.org/operation_3891"
                },
                {
                    "term": "Deisotoping",
                    "uri": "http://edamontology.org/operation_3629"
                }
            ]
        }
    ],
    "labels": {
        "topic": [
            {
                "term": "MRI",
                "uri": "http://edamontology.org/topic_3444"
            },
            {
                "term": "Medical imaging",
                "uri": "http://edamontology.org/topic_3384"
            },
            {
                "term": "Pathology",
                "uri": "http://edamontology.org/topic_0634"
            }
        ]
    },
    "link": [
        {
            "type": "Other",
            "url": "http://adni.loni.usc.edu/adni-3/"
        }
    ],
    "publication": [
        {
            "doi": "10.3389/FNCOM.2019.00054",
            "pmcid": "PMC6700386",
            "pmid": "31456676"
        }
    ],
    "summary": {
        "biotoolsCURIE": "biotools:ADNI-3",
        "biotoolsID": "ADNI-3",
        "description": "> CORRECT NAME OF TOOL COULD ALSO BE 'AD N', 'associated dementia', 'thevirtualbrain.org neuroinformatics', 'Virtual Brain' | Linking Molecular Pathways and Large-Scale Computational Modeling to Assess Candidate Disease Mechanisms and Pharmacodynamics in Alzheimer's Disease | Alzheimer's Disease Neuroimaging Initiative | Alzheimer’s Disease Neuroimaging Initiative | ADNI3 began in 2016 and includes scientists at 59 research centers in the United States and Canada. Between 1070-2000 participants will be enrolled: approximately 700-800 rollover participants from ADNI2 and 370-1200 newly enrolled subjects. Clinical, cognitive, imaging, biomarker and genetic characteristics will be assessed across three cohorts: Cognitively normal, MCI and mild AD dementia | The Alzheimer’s Disease Neuroimaging Initiative (ADNI) unites researchers with study data as they work to define the progression of Alzheimer’s disease (AD)",
        "homepage": "http://adni.loni.usc.edu",
        "name": "ADNI-3"
    }
}